Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;91(6):278-287.
doi: 10.4174/astr.2016.91.6.278. Epub 2016 Nov 25.

Medullary thyroid carcinoma: a 30-year experience at one institution in Korea

Cho Rok Lee  1 , Sohee Lee  2 , Haiyoung Son  3 , Eunjeong Ban  1 , Sang-Wook Kang  1 , Jandee Lee  1 , Jong Ju Jeong  1 , Kee-Hyun Nam  1 , Woong Youn Chung  1 , Cheong Soo Park  1
Affiliations

Medullary thyroid carcinoma: a 30-year experience at one institution in Korea

Cho Rok Lee et al. Ann Surg Treat Res. 2016 Dec.

Abstract

Purpose: The objective of this study was to review the clinical outcome and prognosis of patients with sporadic and hereditary medullary thyroid cancer (MTC) who were treated at a single tertiary hospital in Korea.

Methods: We retrospectively reviewed the case files of 85 patients treated from August 1982 to February 2012.

Results: In all, 65 patients (76.5%) had sporadic MTC and 20 patients (23.5%) had hereditary MTC. Patients in the sporadic group were older than in the hereditary group (P < 0.001). However, the hereditary group had more tumor multiplicity (P < 0.001) and bilaterality (P < 0.001). Neither survival rate was significantly different between the sporadic and hereditary groups (P = 0.775 and P = 0.866). By multivariate analysis, distant metastasis was a significant prognostic factor for overall and progression-free survival.

Conclusion: In general, patients with MTC have favorable outcomes. Distant metastasis appears to be the strongest predictor of overall and progression-free survival.

Keywords: Familial medullary thyroid carcinoma; Prognosis; Survival.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. Overall survival rates in patients with medullary thyroid carcinoma (P = 0.775).
Fig. 2
Fig. 2. Progression-free survival of patients with medullary thyroid carcinoma (P = 0.866).
Fig. 3
Fig. 3. RET proto-oncogene genetic screening and counseling. *Patients underwent thyroid operation from January 1982 to February 2012.
See this image and copyright information in PMC

References

    1. Bachelot A, Lombardo F, Baudin E, Bidart JM, Schlumberger M. Inheritable forms of medullary thyroid carcinoma. Biochimie. 2002;84:61–66. - PubMed
    1. Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010;22:475–485. - PubMed
    1. Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg. 1986;73:278–281. - PMC - PubMed
    1. Wells SA, Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610. - PMC - PubMed
    1. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139–1148. - PubMed

LinkOut - more resources